Elicio Therapeutics, Inc. (ELTX) Earnings History
Annual and quarterly earnings data from 2012 to 2025
Loading earnings history...
ELTX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
ELTX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | 95.6% | -138.8% | -93.2% |
Download Data
Export ELTX earnings history in CSV or JSON format
Free sign-in required to download data
Elicio Therapeutics, Inc. (ELTX) Earnings Overview
As of May 8, 2026, Elicio Therapeutics, Inc. (ELTX) reported trailing twelve-month net income of -$40M, reflecting +39.3% year-over-year growth. The company earned $-2.58 per diluted share over the past four quarters.
Looking at the long-term picture, ELTX's historical earnings data spans multiple years. The company achieved its highest annual net income of $632,241 in fiscal 2013.
Elicio Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including IMVT (-$464M net income), NKTR (-$164M net income, -297.1% margin), ADCT (-$137M net income, -175.3% margin), ELTX has comparable earnings metrics. Compare ELTX vs IMVT →
ELTX Earnings vs Peers
Earnings metrics vs comparable public companies
ELTX Historical Earnings Data (2012–2025)
10 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$40M | +23.8% | -$38M | $-2.58 | - | - |
| 2024 | -$52M | -47.5% | -$45M | $-4.25 | - | - |
| 2023 | -$35M | -24.8% | -$36M | $-6.96 | - | - |
| 2022 | -$28M | -6.8% | -$24M | $-9.10 | - | - |
| 2021 | -$26M | +67.0% | -$39M | $-19.32 | -93.2% | -138.8% |
| 2020 | -$80M | -97.0% | -$55M | $-1.93 | -2781.5% | -1919.2% |
| 2019 | -$41M | -103.0% | -$39M | $-1.50 | -2734.2% | -2595.2% |
| 2018 | -$20M | -3267.3% | -$14M | $-6.79 | -497.0% | -356.0% |
| 2013 | $632,241 | +105.7% | $-397,800 | $103.31 | 9.6% | -6.0% |
| 2012 | $307,303 | - | $-419,220 | $50.21 | 4.2% | -5.7% |
See ELTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ELTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ELTX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonELTX — Frequently Asked Questions
Quick answers to the most common questions about buying ELTX stock.
Is ELTX growing earnings?
ELTX EPS is $-2.58, with earnings growth accelerating to +39.3%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-40M.
What are ELTX's profit margins?
Elicio Therapeutics, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are ELTX's earnings?
ELTX earnings data spans 2012-2025. The accelerating earnings trend is +39.3% YoY. Historical data enables comparison across business cycles.